The Evolving Role of BTKi’s in CLL
Tuesday, June 28, 2022
10 AM PT / 11 PM MT / 12 PM CT / 1 PM ET (Duration 60 minutes)
The targeted therapy Bruton tyrosine kinase inhibitors (BTKi’s) have come a long way since revolutionizing CLL treatment with the arrival of ibrutinib. There are now other BTKi options such as acalabrutinib, zanubrutinib, and the next generation non-covalent BTK Inhibitor, pirtobrutinib. Join CLL Society and Dr. Matthew Davids from Dana Farber Cancer Institute to take a deep dive into different BTKi’s, how they work, how they compare to each other and other treatment options, potential side effects, and the future role of these therapies.
Brian Koffman, MDCM (retired), MS Ed
Co-Founder, Executive Vice President, and Chief Medical Officer
Matthew S. Davids, MD, MMSc
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana Farber Cancer Institute
This program was made possible by grant support from AstraZeneca, BeiGene, Pharmacyclics, and Janssen.